mondoBIOTECH: The Board of Directors calls an Extraordinary Shareholders' Meeting to decide on the creation of a single share type
mondoBIOTECH holding AG announces that the Board of Directors has called an extraordinary shareholders' meeting for 14 September 2011 to decide on the proposal of the Board of Directors to create a single share type.
- (1888PressRelease) August 18, 2011 - The Board of Directors proposes:
1. to create a single share type through the abolishment of the existing registered voting right shares and the splitting of the existing 1'601'602 registered common shares with a par value of CHF 0.10 each into 16'016'020 registered shares with a par value of CHF 0.01 each; and
2. to approve certain amendments to the Company's articles of incorporation in connection with the creation of a single share type.
After the proposed transaction, the share capital of the Company will consist of only one class of registered shares, each having a nominal value of CHF 0.01. The Company will apply for the listing of all 68'917'580 registered shares of the Company according to the Main Standard of SIX Swiss Exchange.
The Board of Directors believes that in addition to becoming a fully public Company with all shares listed on SIX Swiss Exchange, the creation of a single share type will also increase the liquidity of mondoBIOTECH's shares and make them more attractive for investors.
About mondoBIOTECH
mondoBIOTECH holding AG (SIX Swiss Exchange ticker symbol: RARE), an independent Swiss biotech company, discovers drugs for patients suffering from rare diseases through its proprietary Search&Match methodology. Search&Match enables mondoBIOTECH's scientists to combine their unique knowledge of biologically active human peptides with advanced technology solutions delivering medicinal product candidates for rare diseases to licensing partners.
Furthermore, mondoBIOTECH continues to build and expand a growing Community of leading physicians and researchers who dedicate their life to rare diseases. This Rare Community also includes patients and patient advocacy organizations who share their experiences, know-how, expertise and skills with the mondoBIOTECH team and support them in their mission.
Contact
mondoBIOTECH holding AG
Investor Relations, Mr. Paolo Bassanini
Das Kloster
Muergstrasse 18
CH-6370 Stans
Tel.: +41 (0) 840 200 010
Fax: +41 (0) 840 200 011
investor ( @ ) mondobiotech dot com
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning mondoBIOTECH holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of mondoBIOTECH holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. mondoBIOTECH holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam